ÂÜÀòÂÒÂ×

David Breckenridge is currently serving as the Chief Scientific Officer and Chief Business Officer at Actio Biosciences, Inc. Prior to this, David held various positions at Gilead Sciences, including Vice President of Research External Innovation. Throughout their career, David has been involved in leading research projects focused on fibrosis, cardiovascular and renal fibrosis, as well as overseeing the development of inhibitors such as Alobresib and Selonsertib. David's educational background includes a PhD in Biochemistry from McGill University and a Bachelor of Science in Biochemistry from Dalhousie University.